Lead Sponsor

University of Michigan Rogel Cancer Center

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adult patients over 18 years of age with locally advanced or recurrent orbital or periorbital basal cell carcinoma (BCCA), or a medial canthal BCCA that threatens the lacrimal drainage system.
•Clinical assessment score obtained at baseline.
•Medical Oncology screening performed at baseline.
•Adequate BCCA size and location.
•Adequate hematopoietic capacity, hepatic and renal function.
•Male patients must agree to use condoms during treatment and for 3 months after last dose.
•Male patients must agree to not donate sperm during treatment and for 3 months after last dose.
•Participant must agree not to donate blood during the study and for 7 months after last dose.
•Informed consent signed.
•If the patient consents to enroll, then blood will be drawn and stored for biomarker analysis.

•Inability or unwillingness to swallow capsules.
•Inability or unwillingness to comply with study procedures.
•Pregnant, lactating, or breast feeding women.
•Women of childbearing potential.
•Uncontrolled medical illness.
•Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.
•Age under 18 years.